Compare CAVA Group Inc (CAVA) vs Cassava Sciences Inc (FLNA) Price & Performance

CAVA trades at $72.54, up 0.5% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong revenue growth and expansion momentum, but faces high valuation multiples and margin pressures. Recent news highlights aggressive store openings and technology investments driving traffic, though the stock has experienced volatility amid market fluctuations.

Outlook remains growth-focused with analyst consensus bullish, targeting $94.73, but risks include elevated P/E of 134.56, competitive pressures, and potential margin compression from expansion costs. The stock offers upside if execution continues, but requires careful monitoring of profitability trends.

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.